Drugs / Recombinant novel coronavirus vaccine (CHO cell)
Recombinant novel coronavirus vaccine (CHO cell)
also known as
Recombinant novel coronavirus vaccine (CHO cells)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05128643 | Sep 2021 → Apr 2022 | COVID-19 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant novel coronavirus vaccine (CHO cell) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05128643 ↗ |
| Known as | Recombinant novel coronavirus vaccine (CHO cells) | “Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant novel coronavirus vaccine (CHO cells).” NCT05128643 ↗ |
| Modality | Vaccine | “recombinant Novel Coronavirus (COVID-19) vaccine (CHO cell)” NCT05128643 ↗ |
| Route | Intramuscular | “Intramuscular injection of deltoid muscle of upper arm” NCT05128643 ↗ |